News – Sound Bioventures

All Events Fund articles Fund PR Portfolio articles Portfolio PR

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

2025.09.162025.09.16 / Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m upfront and further potential milestone ...

AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer

2025.09.022025.09.02 / Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces to ...

At home in the long, thorny transition from research to product launch

2025.09.012025.09.02 / After almost a decade as a research scientist and then another in pharmaceutical business development and product launch, Anna Gran has unparalleled insight for getting novel therapies to market. At ...

Breye Therapeutics ApS is featured on the latest episode of OptimumTV!

2025.08.212025.08.21 / CEO Ulrik Mouritzen joined Stephen Adams from Optimum Strategic Communications to discuss the successful completion of the Phase 1b study of orally administered hashtag#danegaptide, for the treatment ...

Philip BraininAnalyst, MD, PhD, MBA. Sound Bioventures.

Philip Brainin, Associate at Sound Bioventures, publishes framework in Nature Biotechnology to measure societal impact of venture investments in life sciences

2025.07.172025.09.16 / New model offers groundbreaking metrics for evaluating how early-stage biotech investments translate into patient survival and quality of life gains Copenhagen, Denmark – 17 July 2025 – Philip Bra ...

AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF

2025.07.172025.07.17 / Alignment reached with both the FDA and EMA on key elements of the AC01 development strategy in chronic HFrEF, allowing for a lean, straightforward and coherent plan across both Europe and the USA ...

VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery

2025.07.092025.07.09 / Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation, enabling urgent surgery in patients taking a ...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

2025.06.252025.06.25 / Orally administered treatment was well tolerated, with early signs of clinical activity In models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting

2025.05.092025.05.09 / First small molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers in ...

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

2025.05.072025.05.07 / -Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- - ABO21009’s unique mechanism of action depletes pathogenic T and B ce ...

Linda Spahiu Elvesjö

A polyglot with an international worldview of science and investment

2025.05.062025.05.06 / With previous roles like scientist and startup CEO, Linda Spahiu Elvesjö’s background is ideal for investing in companies that’ll make a difference in patients’ lives and provide strong returns. As P ...

AbolerIS Pharma Announces Formation of Scientific Advisory Board

2025.04.292025.04.30 / Gosselies, Belgium and Nantes, France, April 24, 2025 /PRNewswire/ -- AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering fro ...